In a report released on January 14, Evan Seigerman from BMO Capital reiterated a Hold rating on Replimune Group, with a price target of $11.00. The company’s shares closed yesterday at $7.71.

A critical vulnerability in the popular expr-eval JavaScript library, with over 800,000 weekly downloads on NPM, can be exploited to execute code remotely through maliciously crafted input. The ...

Fintel reports that on November 3, 2025, BMO Capital upgraded their outlook for Replimune Group (NasdaqGS:REPL) from Underperform to Market Perform. As of October 30, 2025, the average one-year price ...

Shares of Replimune Group, Inc. (NASDAQ:REPL) are rising Monday after the clinical stage biotechnology company shared an important regulatory update. What To Know: Replimune said the U.S. Food and ...

On July 22, 2025, Replimune publicly announced that the U.S. Food and Drug Administration (FDA) had issued a "Complete Response Letter" (CRL) for its Biologics License Application (BLA) for RP1. This ...

On July 22, 2025, the U.S. Food and Drug Administration issued a Complete Response Letter for RP1, delaying potential commercialization and revenue. Research and development expenses increased 34.6% ...

On Monday, Replimune Group Inc. (NASDAQ:REPL) is reeling after the FDA unexpectedly rejected its skin cancer treatment, triggering a stock plunge and a wave of investor outrage. Shares fell sharply ...

Ever wondered how JavaScript was created and how it became the world’s most popular programming language?From its early days in Netscape to powering modern web apps, servers, and beyond, this video ...